Nuvation Bio Inc. (NYSE:NUVB) Director Xiangmin Cui Acquires 87,715 Shares

Nuvation Bio Inc. (NYSE:NUVBGet Free Report) Director Xiangmin Cui acquired 87,715 shares of the business’s stock in a transaction on Thursday, June 20th. The shares were bought at an average cost of $2.99 per share, with a total value of $262,267.85. Following the completion of the acquisition, the director now owns 1,762,951 shares of the company’s stock, valued at approximately $5,271,223.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Xiangmin Cui also recently made the following trade(s):

  • On Monday, June 24th, Xiangmin Cui bought 336,874 shares of Nuvation Bio stock. The shares were purchased at an average price of $2.98 per share, with a total value of $1,003,884.52.

Nuvation Bio Stock Performance

NUVB stock opened at $3.03 on Wednesday. The company has a 50 day moving average price of $3.01 and a 200 day moving average price of $2.37. Nuvation Bio Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $4.16.

Nuvation Bio (NYSE:NUVBGet Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. As a group, equities analysts predict that Nuvation Bio Inc. will post -0.31 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on NUVB shares. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Nuvation Bio in a research note on Monday, June 3rd. Royal Bank of Canada increased their price target on Nuvation Bio from $4.00 to $5.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. BTIG Research upgraded Nuvation Bio from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Tuesday, March 26th. Wedbush restated an “outperform” rating and set a $5.00 target price on shares of Nuvation Bio in a report on Friday, May 24th. Finally, Jefferies Financial Group raised Nuvation Bio from a “hold” rating to a “buy” rating and lifted their price target for the company from $1.40 to $10.00 in a report on Wednesday, March 27th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $6.60.

Get Our Latest Stock Report on Nuvation Bio

Institutional Trading of Nuvation Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in NUVB. Gladius Capital Management LP lifted its stake in shares of Nuvation Bio by 92.6% in the 4th quarter. Gladius Capital Management LP now owns 30,967 shares of the company’s stock valued at $47,000 after purchasing an additional 14,885 shares during the period. Beacon Pointe Advisors LLC bought a new stake in Nuvation Bio in the fourth quarter valued at about $33,000. Susquehanna Fundamental Investments LLC acquired a new position in Nuvation Bio in the first quarter valued at about $79,000. Exchange Traded Concepts LLC lifted its stake in Nuvation Bio by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 107,843 shares of the company’s stock valued at $163,000 after buying an additional 27,346 shares during the period. Finally, Pinnacle Wealth Planning Services Inc. bought a new position in Nuvation Bio during the first quarter worth about $105,000. 61.67% of the stock is owned by institutional investors.

Nuvation Bio Company Profile

(Get Free Report)

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

Featured Stories

Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with's FREE daily email newsletter.